Ethyl eicosapentaenoic acid

Drug Profile

Ethyl eicosapentaenoic acid

Alternative Names: eicosapentaenoic acid ethyl ester; EPA-E; Epadel; Epadel-T; ethyl icosapentaenoate; ethyl icosapentate; MND-21

Latest Information Update: 04 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Mochida Pharmaceutical
  • Class Antidepressants; Antihyperlipidaemics; Antiplatelets; Eicosanoids; Esters; Omega 3 fatty acids; Small molecules
  • Mechanism of Action Caspase inhibitors; Phospholipase A2 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Atherosclerosis; Hyperlipidaemia
  • No development reported Chronic heart failure
  • Discontinued Alzheimer's disease; Non-alcoholic steatohepatitis

Most Recent Events

  • 04 Nov 2017 No recent reports of development identified for clinical-Phase-Unknown development in Chronic-heart-failure in Japan (PO)
  • 01 Apr 2014 Clinical trial in Chronic heart failure in Japan (PO)
  • 31 Oct 2012 Mochida Pharmaceutical Company completes a phase II trial in Non-alcoholic steatohepatitis in USA and Puerto Rico (NCT01154985)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top